down arrow

Bellevue Life Sciences Acquisition Corp.

  • Market Cap: N/A
  • Industry: Finance
  • ISIN: US0791741087
USD
0.64
-0.01 (-1.39%)

Dec 12

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.640.66

52 Week

0.4612.54
Valuation
Technical
Day's Volume

CASH

20.32 k

Shareholding (Mar 2025)

FII

3.41%

Held by 8 FIIs

DII

95.97%

Held by 1 DIIs

Promoter

0.00%

How big is Bellevue Life Sciences Acquisition Corp.?

22-Jun-2025

As of Jun 18, Bellevue Life Sciences Acquisition Corp. has a market capitalization of 29.69 million and reported net sales of 0.76 million with a net profit of -13.74 million over the last four quarters.

Market Cap: As of Jun 18, Bellevue Life Sciences Acquisition Corp. has a market capitalization of 29.69 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.76 million and a net profit of -13.74 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds were -6.49 million, and the total assets amounted to 2.30 million.

Read More

What does Bellevue Life Sciences Acquisition Corp. do?

22-Jun-2025

Bellevue Life Sciences Acquisition Corp. is a micro-cap finance company with recent net sales of $1 million and a net loss of $11 million, resulting in a market cap of $29.69 million. It has a P/E ratio of NA due to losses and a dividend yield of 0.00%.

Overview:<BR>Bellevue Life Sciences Acquisition Corp. operates in the finance industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 29.69 Million <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: -6.97% <BR>Price to Book: 0.39 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Bellevue Life Sciences Acquisition Corp. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Bellevue Life Sciences Acquisition Corp. is in a mildly bearish trend, with mixed technical indicators and significant short-term gains of 18.79% over one week and 28.48% over one month, despite a year-to-date decline of 93.56%.

As of 25 August 2025, the technical trend for Bellevue Life Sciences Acquisition Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, while the monthly MACD shows no signal. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are mildly bearish weekly and bearish monthly, and moving averages are bearish on the daily. The KST is bearish weekly with no trend monthly, while the Dow Theory shows a mildly bearish stance weekly and no trend monthly. The OBV is mildly bullish weekly but has no trend monthly.<BR><BR>In terms of performance, the stock has shown a significant 1-week return of 18.79% compared to the S&P 500's 1.05%, and a 1-month return of 28.48% versus the S&P 500's 2.33%. However, year-to-date, the stock is down 93.56%, while the S&P 500 is up 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared Negative results for the last 5 consecutive quarters

  • INTEREST(9M) At USD 0.1 MM has Grown at inf%
  • NET PROFIT(HY) At USD -2.45 MM has Grown at -1,453.52%
  • ROCE(HY) Lowest at -26.94%
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Finance

stock-summary
Market cap

USD 19 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-999,999.00

stock-summary
Return on Equity

-5.62%

stock-summary
Price to Book

0.23

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.92%
0%
4.92%
6 Months
-59.49%
0%
-59.49%
1 Year
-94.34%
0%
-94.34%
2 Years
-93.88%
0%
-93.88%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Bellevue Life Sciences Acquisition Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Bellevue Life Sciences Acquisition Corp. technically bullish or bearish?

As of 25 August 2025, the technical trend for Bellevue Life Sciences Acquisition Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, while the monthly MACD shows no signal. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are mildly bearish weekly and bearish monthly, and moving averages are bearish on the daily. The KST is bearish weekly with no trend monthly, while the Dow Theory shows a mildly bearish stance weekly and no trend monthly. The OBV is mildly bullish weekly but has no trend monthly. In terms of performance, the stock has shown a significant 1-week return of 18.79% compared to the S&P 500's 1.05%, and a 1-month return of 28.48% versus the S&P 500's 2.33%. However, year-to-date, the stock is down 93.56%, while the S&P 500 is up 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-301.00%
EBIT to Interest (avg)
-2.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
1.52%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.92%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.35
EV to EBIT
-4.90
EV to EBITDA
-7.90
EV to Capital Employed
0.37
EV to Sales
29.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-7.59%
ROE (Latest)
-6.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (0.62%)

Foreign Institutions

Held by 8 Foreign Institutions (3.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -5,100.00% vs -133.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-0.50",
          "chgp": "-480.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-0.10",
          "chgp": "-5,100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,605.10%",
          "val2": "0.00%",
          "chgp": "-460.51%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -700.00% vs 0.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-1.80",
          "chgp": "-94.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "0.40",
          "chgp": "-700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.10
0.00
Operating Profit (PBDIT) excl Other Income
-2.90
-0.50
-480.00%
Interest
0.00
0.00
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-5.20
-0.10
-5,100.00%
Operating Profit Margin (Excl OI)
-4,605.10%
0.00%
-460.51%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -5,100.00% vs -133.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.50
-1.80
-94.44%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.40
0.40
-700.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -700.00% vs 0.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Bellevue Life Sciences Acquisition Corp. stock-summary
stock-summary
Bellevue Life Sciences Acquisition Corp.
Finance
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."